Department of Respiratory and Critical Care and Sleep Medicine, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361101, China.
Institute of Chest and Lung Diseases, Xiang'an Hospital of Xiamen University, Xiamen 361101, China.
ACS Biomater Sci Eng. 2022 Oct 10;8(10):4535-4546. doi: 10.1021/acsbiomaterials.2c00620. Epub 2022 Sep 7.
In nonsmall cell lung cancers (NSCLC), near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) has proven to be an efficient approach for locating pulmonary nodules and pulmonary sentinel lymph nodes. However, due to a lack of tumor selectivity, ICG's use as a photosensitizer for photothermal therapy (PTT) and photodynamic therapy (PDT) is restricted. In the current study, we aimed to develop a type of high-performance NIR nanoparticle formulated with ICG to enhance its targeted efficacy and tumor specificity on NSCLC. An ICG-osimertinib nanoparticle (ICG-Osi) was self-assembled through stacking, with a size of 276 nm and a surface charge of -7.4 mV. The NIR visibility and epidermal growth factor receptor (EGFR) targetability of the ICG-Osi was confirmed by its binding efficiency to EGFR-expressing NSCLC cells and , regardless of EGFR mutation status. The targeted effect was further confirmed in mouse xenograft models and showed an extended tumor retention time (>96 h). We demonstrated a significantly enhanced hyperthermia effect and a retained reactive oxygen species (ROS) generating ability of ICG-Osi, resulting in a 2-fold higher cell death rate than ICG alone. The ICG-Osi down-regulated GPX4 and p62 expression while up-regulating caspase-3 and beclin1 expression in NSCLC cells, indicating a complex network of cell death-related proteins. Considering the merits of simple assembly, EGFR binding efficacy, improved hyperthermia effect, and efficient cancer cell suppression, the ICG-Osi exhibits great potential for clinical application in EGFR-expressing NSCLC therapy.
在非小细胞肺癌(NSCLC)中,使用吲哚菁绿(ICG)的近红外(NIR)荧光成像是定位肺结节和肺前哨淋巴结的有效方法。然而,由于缺乏肿瘤选择性,ICG 作为光热疗法(PTT)和光动力疗法(PDT)的光敏剂的应用受到限制。在本研究中,我们旨在开发一种新型高性能 NIR 纳米颗粒,该颗粒由 ICG 组成,以增强其在 NSCLC 中的靶向疗效和肿瘤特异性。通过堆积自组装形成 ICG-奥希替尼纳米颗粒(ICG-Osi),其粒径为 276nm,表面电荷为-7.4mV。通过 ICG-Osi 与表达表皮生长因子受体(EGFR)的 NSCLC 细胞的结合效率证实了其 NIR 可见性和 EGFR 靶向性,而与 EGFR 突变状态无关。在小鼠异种移植模型中进一步证实了靶向作用,并显示出延长的肿瘤保留时间(>96h)。我们证明了 ICG-Osi 具有显著增强的热疗效果和保留的活性氧(ROS)生成能力,导致细胞死亡率比单独使用 ICG 高 2 倍。ICG-Osi 在 NSCLC 细胞中下调 GPX4 和 p62 的表达,同时上调 caspase-3 和 beclin1 的表达,表明细胞死亡相关蛋白的复杂网络。考虑到其组装简单、EGFR 结合效力、改善的热疗效果和高效的抑制癌细胞的优点,ICG-Osi 在表达 EGFR 的 NSCLC 治疗的临床应用中具有巨大的潜力。